The Transcendence of HT-SPR Technology Across Discovery Platforms and its Impact on Time-to-Clinic

Presentation at Oxford Global Biologics UK 2022 by Andrew Goodhead, PhD

Posted by Andrew Goodhead

In biotherapeutic discovery, traditional hybridoma and phage approaches now both contend with and are complemented by NGS and synthetic strategies to meet candidate timelines measured in weeks rather than years. Despite substantial market pressures driving more sophisticated and differentiated approaches, there are stages in these workflows where turnkey solutions can be implemented to eliminate bottlenecks. In this talk HT-SPR technology will be highlighted as a tool in biotherapeutics discovery that is deployable in any workflow.